LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 240

Search options

  1. Book ; Online: Improving the Cybersecurity of U.S. Air Force Military Systems Throughout Their Life Cycles

    Snyder, Don / Powers, James D / Bodine-Baron, Elizabeth / Fox, Bernard / Kendrick, Lauren

    2015  

    Keywords Network security ; Digital lifestyle ; Air forces & warfare ; Military engineering ; History ; Technology
    Language English
    Size 1 Online-Ressource
    Publisher RAND Corporation
    Document type Book ; Online
    Note English
    HBZ-ID HT030612264
    ISBN 9780833089007 ; 0833089005
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Book ; Online ; Conference proceedings: Assessment of the Air Force Materiel Command Reorganization

    Snyder, Don / Fox, Bernard / Lynch, Kristin F / Conley, Raymond E / Ausink, John A

    Report for Congress

    2013  

    Keywords Military history ; Defence strategy, planning & research ; Politics & government ; History ; Political Science
    Language English
    Size 1 Online-Ressource
    Publisher RAND Corporation
    Document type Book ; Online ; Conference proceedings
    Note English
    HBZ-ID HT030610375
    ISBN 9780833082503 ; 0833082507
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  3. Book ; Online: Improving Air Force Enterprise Resource Planning-Enabled Business Transformation

    Riposo, Jessie / Weichenberg, Guy / Duran, Chelsea Kaihoi / Fox, Bernard / Shelton, William

    2013  

    Keywords Business strategy ; Organizational theory & behaviour ; Military engineering ; Technology ; Business ; Management & Organizational Behavior
    Language English
    Size 1 Online-Ressource
    Publisher RAND Corporation
    Document type Book ; Online
    Note English
    HBZ-ID HT030611757
    ISBN 9780833080387 ; 0833080385
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  4. Article ; Online: Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics.

    Roberts, Graham / Fox, Bernard / Longstaff, Colin

    Vox sanguinis

    2020  Volume 116, Issue 1, Page(s) 99–105

    Abstract: Background: Prekallikrein activator (PKA) is a contaminating enzyme found in therapeutic albumin and immunoglobulin products. The level is commonly measured using methods such as that defined by the European Pharmacopoeia (Ph Eur) with traceability to ... ...

    Abstract Background: Prekallikrein activator (PKA) is a contaminating enzyme found in therapeutic albumin and immunoglobulin products. The level is commonly measured using methods such as that defined by the European Pharmacopoeia (Ph Eur) with traceability to the WHO International Standard for PKA. This method generally works well, but problems are sometimes observed.
    Materials and methods: A simplified one-step method has been developed to replace the existing Ph Eur two-step method which consists of kallikrein generation followed by kallikrein measurement using a chromogenic substrate. Analysis of data from the one-stage method is simplified by the use of a dedicated online app.
    Results: The one-stage method was validated against the current Ph Eur method using batches of albumin and immunoglobulins. Problem batches of immunoglobulins were investigated using the one-stage method. Improved methodology using true initial rate determinations and use of acid-treated prekallikrein substrate (PKS) helped understand and reduce artefactual results.
    Conclusions: The one-stage method and associated app streamline real-time determination of PKA and promote good principles of enzyme assays to limit substrate depletion, while also conserving expensive PKS. Blanking steps and reproducibility are simplified.
    MeSH term(s) Albumins ; Factor XIIa/analysis ; Factor XIIa/metabolism ; Humans ; Immunoglobulins ; Prekallikrein/metabolism ; Reproducibility of Results
    Chemical Substances Albumins ; Immunoglobulins ; Prekallikrein (9055-02-1) ; Factor XIIa (EC 3.4.21.38)
    Language English
    Publishing date 2020-09-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.12980
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: International collaborative study to evaluate and calibrate two recombinant L chain Ferritin preparations for use as a WHO International Standard.

    Fox, Bernard / Roberts, Graham / Atkinson, Eleanor / Rigsby, Peter / Ball, Christina

    Clinical chemistry and laboratory medicine

    2021  Volume 60, Issue 3, Page(s) 370–378

    Abstract: Objectives: To evaluate and calibrate two candidate preparations for the 4th International Standard for Ferritin (Human, Recombinant) (codes: 19/118 and 19/162) against the 3rd International Standard for Ferritin (Human, Recombinant) (code: 94/572), and ...

    Abstract Objectives: To evaluate and calibrate two candidate preparations for the 4th International Standard for Ferritin (Human, Recombinant) (codes: 19/118 and 19/162) against the 3rd International Standard for Ferritin (Human, Recombinant) (code: 94/572), and three serum commutability samples in an international collaborative study involving 12 laboratories in nine countries.
    Methods: Eleven of the 12 participating laboratories performed Ferritin quantitation using automated assay platforms and one laboratory used a manual ELISA kit.
    Results: There was better overall agreement between all laboratories and between assay methods for the potency of preparation 19/118 than for preparation 19/162. The overall geometric mean potency (from all methods) of the candidate 4th International Standard, 19/118, was 10.5 µg/ampoule, with inter-laboratory variability, expressed as % geometric coefficient of variation (GCV), of 4.7%. Accelerated stability studies have predicted both 19/118 and 19/162 to be very stable for long term storage at -20 °C.
    Conclusions: The candidate 4th International Standard for Ferritin (Human, Recombinant) (19/118) has been shown to be immunologically similar to the 3rd International Standard for Ferritin (Human, Recombinant) (94/572). It was recommended to and accepted by the WHO Expert Committee on Biological Standardization that 19/118 be established as the 4th International Standard for Ferritin (Human, Recombinant) with an assigned potency of 10.5 µg/ampoule and expanded uncertainty limits 10.2-10.8 µg/ampoule (95% confidence;
    MeSH term(s) Biological Assay ; Ferritins ; Humans ; Laboratories ; Reference Standards ; World Health Organization
    Chemical Substances Ferritins (9007-73-2)
    Language English
    Publishing date 2021-12-17
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1418007-8
    ISSN 1437-4331 ; 1434-6621 ; 1437-8523
    ISSN (online) 1437-4331
    ISSN 1434-6621 ; 1437-8523
    DOI 10.1515/cclm-2021-1139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.

    Ascierto, Paolo A / Brentjens, Renier / Khleif, Samir N / Odunsi, Kunle / Rezvani, Katayoun / Ruella, Marco / Sullivan, Ryan J / Fox, Bernard A / Puzanov, Igor

    Journal of translational medicine

    2023  Volume 21, Issue 1, Page(s) 275

    Abstract: The 2022 Immunotherapy Bridge congress (November 30-December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and ... ...

    Abstract The 2022 Immunotherapy Bridge congress (November 30-December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy. As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate.
    MeSH term(s) Humans ; Immunotherapy ; Neoplasms/therapy ; Immunotherapy, Adoptive ; T-Lymphocytes ; Biomarkers, Tumor ; Tumor Microenvironment
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2023-04-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2118570-0
    ISSN 1479-5876 ; 1479-5876
    ISSN (online) 1479-5876
    ISSN 1479-5876
    DOI 10.1186/s12967-023-04117-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.

    Fox, Bernard A / Urba, Walter J / Jensen, Shawn M / Page, David B / Curti, Brendan D / Sanborn, Rachel E / Leidner, Rom S

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 29, Issue 12, Page(s) 2173–2175

    Abstract: The authors of a recent study identified noncanonical peptides (NCP) presented by cancer cells' HLA and observed lack of reactivity to these antigens by endogenous tumor-reactive T cells. In vitro sensitization generated NCP-reactive T cells that ... ...

    Abstract The authors of a recent study identified noncanonical peptides (NCP) presented by cancer cells' HLA and observed lack of reactivity to these antigens by endogenous tumor-reactive T cells. In vitro sensitization generated NCP-reactive T cells that recognized epitopes shared by a majority of cancers tested, providing opportunities for novel therapies to shared antigens. See related article by Lozano-Rabella et al., p. 2250.
    MeSH term(s) Humans ; Antigens, Neoplasm/immunology ; Melanoma/immunology ; Ligands ; Lighting ; Proteogenomics ; Peptides
    Chemical Substances Antigens, Neoplasm ; Ligands ; Peptides
    Language English
    Publishing date 2023-04-11
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-0422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

    Di Giacomo, Anna Maria / Lahn, Michael / Eggermont, Alexander Mm / Fox, Bernard / Ibrahim, Ramy / Sharma, Padmanee / Allison, James P / Maio, Michele

    European journal of cancer (Oxford, England : 1990)

    2023  Volume 198, Page(s) 113501

    Abstract: The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council, included a focus on the future of ... ...

    Abstract The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council, included a focus on the future of integrating and expanding the use of targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The conference members exchanged their views on the lessons from targeting CTLA-4 and compared the effect to the impact of blocking Programmed cell death protein 1 (PD1) or its ligand (PDL1). The increasing experience with both therapeutic approaches and their combination suggests that targeting CTLA-4 may lead to more durable responses for a sizeable proportion of patients, though the specific mechanism is not entirely understood. Overcoming toxicity of blocking CTLA-4 is currently being addressed with different doses and dose regimens, especially when combined with PD1/PDL1 blocking antibodies. Novel therapeutics targeting CTLA-4 hold the promise to reduce toxicities and thus allow different combination strategies in the future. On the whole, the consent was that targeting CTLA-4 remains an important strategy to improve the efficacy of cancer immunotherapies.
    MeSH term(s) Humans ; CTLA-4 Antigen ; T-Lymphocytes, Cytotoxic ; Neoplasms/drug therapy ; Italy ; Immunotherapy
    Chemical Substances CTLA-4 Antigen
    Language English
    Publishing date 2023-12-21
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2023.113501
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Relationships matter in oral cancer: will single-stain immunohistochemistry become irrelevant in the age of multispectral imaging?

    Bell, R Bryan / Fox, Bernard A

    Oral surgery, oral medicine, oral pathology and oral radiology

    2017  Volume 124, Issue 6, Page(s) 517–518

    MeSH term(s) Biomarkers, Tumor/immunology ; CD3 Complex/immunology ; CD8-Positive T-Lymphocytes/immunology ; Carcinoma, Squamous Cell/diagnostic imaging ; Carcinoma, Squamous Cell/immunology ; Diagnostic Imaging ; Humans ; Immunohistochemistry/methods ; Mouth Neoplasms/diagnostic imaging ; Mouth Neoplasms/immunology ; Prognosis ; Risk Assessment ; Survival Rate
    Chemical Substances Biomarkers, Tumor ; CD3 Complex
    Language English
    Publishing date 2017
    Publishing country United States
    Document type Editorial
    ZDB-ID 2650843-6
    ISSN 2212-4411 ; 2212-4403
    ISSN (online) 2212-4411
    ISSN 2212-4403
    DOI 10.1016/j.oooo.2017.09.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The British Standard for (European Conformity[CE] Marked) Anti-D: Its rarely discussed but important role in quantitating anti-D in patient plasma.

    Fox, Bernard / Hockley, Jason / Studholme, Lucy

    Transfusion medicine (Oxford, England)

    2019  Volume 30, Issue 1, Page(s) 75–77

    MeSH term(s) Blood Grouping and Crossmatching/standards ; Humans ; Plasma ; Reference Standards ; Rh-Hr Blood-Group System/blood ; Rho(D) Immune Globulin/blood ; United Kingdom
    Chemical Substances RHO(D) antibody ; Rh-Hr Blood-Group System ; Rho(D) Immune Globulin
    Language English
    Publishing date 2019-11-26
    Publishing country England
    Document type Letter
    ZDB-ID 1067989-3
    ISSN 1365-3148 ; 0958-7578
    ISSN (online) 1365-3148
    ISSN 0958-7578
    DOI 10.1111/tme.12649
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top